FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

https://ir.intelliatx.com/news-releases/news-release-details/fda-accepts-investigational-new-drug-application-crisprcas9
JOIN OUR MAILING LIST